Articles related to Oncology, Surgical

The encouraging results of the phase 3 ORIENT-11 trial, which included 397 patients with previously untreated, locally advanced metastatic non-squamous NSCLC without sensitizing EGFR or ALK aberrations, were published in the Journal of Thoracic Oncology.

Studies suggest that G12C mutations occur in 3% to 8% of total colorectal cancer (CRC) cases and constitute 6% to 17% of KRAS mutations. Having a G12C mutation may be an adverse prognostic factor in mCRC, but confounding factors may be more responsible for differences in treatment outcomes than the G12C mutation itself. The two conflicting presentations at the ESMO World Congress on Gastrointestinal Cancer highlight the critical need to define the prognostic significance of the G12C mutation and the resulting treatment implications more precisely.

Using data from Swedish family cancer datasets to calculate standardized incidence ratios (SIRs) and the cumulative risk of invasive colorectal cancer (CRC) in first- and second-degree relatives of people with colorectal carcinoma in situ (CCIS) or invasive CRC, the Journal of the National Comprehensive Cancer Network (JNCCN) suggests that family history of CCIS should be considered similarly to family history of invasive CRC in risk stratification for earlier CRC screening.

The case reported is based on a 53-year-old woman who presented to her gastroenterologist with symptoms of bowel obstruction and right upper quadrant pain. Based on her age and excellent performance status, aggressive treatment with a triplet chemotherapy regimen of oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (FOLFOXIRI) in combination with the anti–vascular endothelial growth factor receptor antibody bevacizumab was begun.

According to a study published online in Neurology, in the 6 months after a colorectal cancer (CRC) diagnosis, patients with multiple sclerosis (MS) have an increased risk of all-cause and cancer-specific death. Data were included for 338 MS cases and 1,352 controls without MS, matched for birth year, sex, cancer diagnosis year, and region.

Having a child with cancer is one of the most stressful events for any parent to endure. And, according to a report in JAMA Network Open, that stress contributes to often fractious relationships between parents and the medical teams treating their cancer-stricken children. JAMA reports that a quarter of parents have a difficult, or challenging, relationship with their pediatric oncologist and related medical team. The study also found that the tense feelings are mutual between parents and doctors. Among physicians surveyed, 37.6% reported that they felt the relationships they had with parents of the children they treated were challenging.